IPO News Archive

Cempra prices IPO at $6, below the range

2/3/12


Cempra, a biotech developing potent antibiotics to fight pneumonia and skin infections, raised $50 million by offering 8.4 million shares at $6, below the range of $11 to $13. The company had originally planned to sell 6 million shares. Cempra plans to list on the NASDAQ under the symbol CEMP. Stifel Nicolaus Weisel, Leerink Swann and Cowen & Company acted as lead managers on the deal.

Keywords/Tickers: CEMP
Related Links: Recently Priced IPOs
Source: www.RenaissanceCapital.com
blog comments powered by Disqus
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital, Greenwich, CT (www.renaissancecapital.com).
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital and/or the Global IPO Fund (symbol: IPOSX) may have investments in securities of companies mentioned.
Invest in Global IPO Fund
About Fund Prospectus Invest